Epizyme To Participate in H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwal, Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference.

A pre-recorded fireside chat will be available to play on demand stating at 7:00am EST on Tuesday, May 24, 2022. It can be found in the investor section of the Company’s website at www.epizyme.com and will be archived after 60 days following the presentation.

About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit www.epizyme.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005278/en/

Media: Erin Graves
[email protected]
(617) 500-0615

Investors: Caitlin Stern
[email protected]

Source: Epizyme, Inc.

You May Also Be Interested In

• MLF Announces Launch of New Multi-Year Sponsorship and Licensing Partnership with REDCON1
• HELIOS® by VirtualHealth Named Bronze Stevie® Award Winner in 2024 American Business Awards®
• Hydrogen Fuel Cells Market Size is Projected to Reach USD 16.41 Billion by 2031 | SNS Insider